First-half revenue at animal pharmaceutical group Dechra (DPH) is expected to come in ahead of analyst expectations. A trading update revealed a 56 per cent increase in reported revenue compared with the first half of the 2016 financial year as the group benefited from acquisitions and a favourable currency environment.
IC TIP:
Buy
at
1422p
Revenue at all four of the group's recently acquired businesses have beaten management expectations, with Putney helping to boost US constant-currency sales by 112 per cent. The new businesses are also helping to progress the pipeline. Dechra recently launched generic canine antibiotic Amoxi-clav - a drug the group gained with the Putney acquisition - into the US where its addressable market is an estimated $50m (£41m).
